Early US Experience Using the Symani for Robotic‐Assisted Microvascular Surgery
Microsurgery · 2026-12 · 46 (8)
DOI: 10.1002/micr.70319 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Microsurgery, online erschienen am 16.11.2026. Verfasst von Arturo J Rios-Diaz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Microsurgery, Robotic Surgical Procedures, Plastic Surgery Procedures, Vascular Surgical Procedures. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
Robotic‐assisted microsurgery provides motion scaling, tremor filtration, and enhanced visualization, offering potential advantages for complex microsurgical tasks. Following Food and Drug Administration authorization, the Symani Surgical System was introduced into clinical practice in the United States in April 2024. This study presents the first multi‐institutional US experience with Symani, evaluating feasibility, reconstructive outcomes, and technical challenges during its inaugural year of use in the United States.
Methods
All robotic‐assisted procedures performed between April 2024 and April 2025 at two tertiary academic centers were retrospectively reviewed. Demographics, clinical indications, flap type, and anastomotic details were extracted. Primary outcomes were anastomotic patency and flap loss. Secondary outcomes included overall surgical complications and conversion to conventional microsurgery.
Results
Twenty‐seven patients underwent robotic‐assisted microsurgical procedures. Median age was 51 [IQR 39–63] years; 55.6% were female, and 74.1% identified as White. Indications included oncologic reconstruction (48.1%), trauma (18.5%), degenerative bony disease (14.8%), infection (11.1%), peripheral vascular disease (3.7%), and morphea (3.7%). A wide variety of flaps were performed, most commonly deep inferior epigastric perforator (DIEP) (44.4%), free vascularized fibular grafts (18.5%), and scapular flaps (14.8%). Robotic assistance was employed for 27 arterial anastomoses (84.4%), three venous anastomoses (9.4%), and two nerve coaptations (6.3%). Anastomotic configuration was predominantly end‐to‐end (71.9%). No flap loss occurred. One patient (3.7%) required re‐exploration for pedicle kinking. Two conversions to conventional non‐robotic microsurgery were required (7.4%).
Conclusions
Early US multi‐institutional experience demonstrates the Symani system is feasible and safe across diverse reconstructive procedures, enabling reliable microvascular anastomoses and nerve coaptations with minimal complications and no flap loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Plastic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Orthopedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Arturo J Rios-Diaz, Sarah N Bishop, Berk B Ozmen, Diwakar Phuyal, Risal S Djohan, Graham S Schwarz, L Scott Levin
Zitieren
APA
Rios-Diaz, A. J., Bishop, S. N., Ozmen, B. B., Kovach, S. J., Lin, I., Phuyal, D., Rose, J. F., Djohan, R. S., Schwarz, G. S., & Levin, L. S. (2026). Early US Experience Using the Symani for Robotic‐Assisted Microvascular Surgery. Microsurgery, 46(8). https://doi.org/10.1002/micr.70319
Vancouver
Rios-Diaz AJ, Bishop SN, Ozmen BB, Kovach SJ, Lin I, Phuyal D, et al. Early US Experience Using the Symani for Robotic‐Assisted Microvascular Surgery. Microsurgery. 2026;46(8). doi:10.1002/micr.70319
BibTeX
@article{RiosDiaz2026,
author = {Rios-Diaz, Arturo J and Bishop, Sarah N and Ozmen, Berk B and Kovach, Stephen J and Lin, Ines and Phuyal, Diwakar and Rose, Jessica F and Djohan, Risal S and Schwarz, Graham S and Levin, L Scott},
title = {Early US Experience Using the Symani for Robotic‐Assisted Microvascular Surgery},
journal = {Microsurgery},
year = {2026},
volume = {46},
number = {8},
doi = {10.1002/micr.70319}
}
EUVIMED